Background Chronic heart failure (HF) is a prevalent world‐wide. Angiotensin receptor
blockers (ARBs) are widely prescribed for chronic HF although their role is controversial …

The magnitude of the clinical benefits produced by inhibitors of the renin-angiotensin system
in heart failure has been modest, possibly because of the ability of renin-angiotensin activity …

Apelin, the endogenous ligand of the G protein-coupled APJ receptor, is a peptide mediator
with emerging regulatory actions in the heart. The aim of the present studies was to explore …

Background Apoptosis is a major cause of ischemic heart dysfunction. Apelin, the
endogenous ligand for the G-protein-coupled APJ receptor, has been reported to exert …

When fish are processed, fish bone becomes a key component of the waste, but to date very
few researchers have sought to use fish bone to prepare protein hydrolysates as a means of …

Pharmacotherapy in chronic heart failure (HF) is challenging, due to the diverse
neuroendocrine, inflammatory, metabolic and immunological mechanisms involved in its …

Chronic heart failure (CHF) is a key part of cardiovascular continuum. Under the guidance of
the theory of vessel-collateral doctrine, the present study proposes therapeutic benefits of …

The NHS wastes billions on “me too” drugs that confer little or no added therapeutic benefit.
James Moon and colleagues propose a way to restructure healthcare prescribing to get …

Diastolic heart failure (DHF) is estimated to occur in 40% to 50% of patients with heart
failure. Evidence suggests that DHF is primarily a cardiogeriatric syndrome that increases …

Our previous work revealed the protective effect of Qiliqiangxin (QLQX) on cardiac
microvascular endothelial cells (CMECs), but the underlying mechanisms remain unclear …